Skip to main content
NCBI home page
The Yale Journal of Biology and Medicine logoLink to The Yale Journal of Biology and Medicine
. 1996 May-Jun;69(3):245–259.

CCKB/gastrin receptor antagonists: recent advances and potential uses in gastric secretory disorders.

R T Jensen 1
PMCID: PMC2589015  PMID: 9165693

Abstract

Cholecystokinin (CCK) and the structurally related peptide, gastrin, have numerous effects on tissues in the central nervous system and gastrointestinal tract. Recent studies show these effect are mediated by a CCKA and CCKB receptor. Knowledge of the physiological role and role of CCKB receptors in pathologic processes has been particularly limited by the availability of selective, potent receptor antagonists. Recently, new members of five different classes of non-peptide CCKB receptor antagonists are reported and are reviewed briefly. these include compounds isolated from Streptomyces (tetronothiodin, virginiamycin analogues), ureido-acetamide analogues (RP 69758, RP 72540, RP 73870), newer benzodiazepine analogues (L-368,935, L-740,093, YM022), pyrazolidimine analogues (LY 262,691) and glutamic acid analogues (CR2194). Many of these compounds have greater than 1000-fold selectivity for the CCKB over the CCKA receptor and some have greater than 10,000-fold selectivity. The pharmacology and effects of CCKB receptor antagonists on gastric acid secretion is briefly reviewed. Furthermore, the possible clinical usefulness of CCKB receptor antagonists in treating disorders of gastric acid secretion, in inhibiting the trophic effects of gastrin and in other clinical conditions is briefly discussed.

Full text

PDF
245

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beglinger C., Hildebrand P., Meier R., Bauerfeind P., Hasslocher H., Urscheler N., Delco F., Eberle A., Gyr K. A physiological role for cholecystokinin as a regulator of gastrin secretion. Gastroenterology. 1992 Aug;103(2):490–495. doi: 10.1016/0016-5085(92)90838-p. [DOI] [PubMed] [Google Scholar]
  2. Beinborn M., Lee Y. M., McBride E. W., Quinn S. M., Kopin A. S. A single amino acid of the cholecystokinin-B/gastrin receptor determines specificity for non-peptide antagonists. Nature. 1993 Mar 25;362(6418):348–350. doi: 10.1038/362348a0. [DOI] [PubMed] [Google Scholar]
  3. Bertrand P., Böhme G. A., Durieux C., Guyon C., Capet M., Jeantaud B., Boudeau P., Ducos B., Pendley C. E., Martin G. E. Pharmacological properties of ureido-acetamides, new potent and selective non-peptide CCKB/gastrin receptor antagonists. Eur J Pharmacol. 1994 Sep 12;262(3):233–245. doi: 10.1016/0014-2999(94)90737-4. [DOI] [PubMed] [Google Scholar]
  4. Bock M. G., DiPardo R. M., Mellin E. C., Newton R. C., Veber D. F., Freedman S. B., Smith A. J., Patel S., Kemp J. A., Marshall G. R. Second-generation benzodiazepine CCK-B antagonists. Development of subnanomolar analogs with selectivity and water solubility. J Med Chem. 1994 Mar 18;37(6):722–724. doi: 10.1021/jm00032a003. [DOI] [PubMed] [Google Scholar]
  5. Bock M. G., DiPardo R. M., Newton R. C., Bergman J. M., Veber D. F., Freedman S. B., Smith A. J., Chapman K. L., Patel S., Kemp J. A. Selective non-peptide ligands for an accommodating peptide receptor. Imidazobenzodiazepines as potent cholecystokinin type B receptor antagonists. Bioorg Med Chem. 1994 Sep;2(9):987–998. doi: 10.1016/s0968-0896(00)82047-7. [DOI] [PubMed] [Google Scholar]
  6. Bradwejn J., Koszycki D., Couëtoux du Tertre A., van Megen H., den Boer J., Westenberg H. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch Gen Psychiatry. 1994 Jun;51(6):486–493. doi: 10.1001/archpsyc.1994.03950060050005. [DOI] [PubMed] [Google Scholar]
  7. Bradwejn J. Neurobiological investigations into the role of cholecystokinin in panic disorder. J Psychiatry Neurosci. 1993 Jul;18(4):178–188. [PMC free article] [PubMed] [Google Scholar]
  8. Böhme G. A., Bertrand P., Guyon C., Capet M., Pendley C., Stutzmann J. M., Doble A., Dubroeucq M. C., Martin G., Blanchard J. C. The ureidoacetamides, a novel family of non-peptide CCK-B/gastrin antagonists. Ann N Y Acad Sci. 1994 Mar 23;713:118–120. doi: 10.1111/j.1749-6632.1994.tb44057.x. [DOI] [PubMed] [Google Scholar]
  9. Chang R. S., Lotti V. J., Monaghan R. L., Birnbaum J., Stapley E. O., Goetz M. A., Albers-Schönberg G., Patchett A. A., Liesch J. M., Hensens O. D. A potent nonpeptide cholecystokinin antagonist selective for peripheral tissues isolated from Aspergillus alliaceus. Science. 1985 Oct 11;230(4722):177–179. doi: 10.1126/science.2994227. [DOI] [PubMed] [Google Scholar]
  10. Charpentier B., Pelaprat D., Durieux C., Dor A., Reibaud M., Blanchard J. C., Roques B. P. Cyclic cholecystokinin analogues with high selectivity for central receptors. Proc Natl Acad Sci U S A. 1988 Mar;85(6):1968–1972. doi: 10.1073/pnas.85.6.1968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Chuang C. N., Tanner M., Chen M. C., Davidson S., Soll A. H. Gastrin induction of histamine release from primary cultures of canine oxyntic mucosal cells. Am J Physiol. 1992 Oct;263(4 Pt 1):G460–G465. doi: 10.1152/ajpgi.1992.263.4.G460. [DOI] [PubMed] [Google Scholar]
  12. Coy D., Wang L. H., Jiang N. Y., Jensen R. Short chain bombesin pseudopeptides with potent bombesin receptor antagonist activity in rat and guinea pig pancreatic acinar cells. Eur J Pharmacol. 1990 Nov 6;190(1-2):31–38. doi: 10.1016/0014-2999(90)94109-b. [DOI] [PubMed] [Google Scholar]
  13. Creutzfeldt W. The achlorhydria-carcinoid sequence: role of gastrin. Digestion. 1988;39(2):61–79. doi: 10.1159/000199609. [DOI] [PubMed] [Google Scholar]
  14. DelValle J., Chiba T., Park J., Yamada T. Distinct receptors for cholecystokinin and gastrin on canine fundic D-cells. Am J Physiol. 1993 May;264(5 Pt 1):G811–G815. doi: 10.1152/ajpgi.1993.264.5.G811. [DOI] [PubMed] [Google Scholar]
  15. Dickinson C. J. Relationship of gastrin processing to colon cancer. Gastroenterology. 1995 Oct;109(4):1384–1388. doi: 10.1016/0016-5085(95)90603-7. [DOI] [PubMed] [Google Scholar]
  16. Eissele R., Koop H., Bothe-Sandfort E., Arnold R. Effect of gastrin receptor antagonists on gastric acid secretion and gastrin and somatostatin release in the rat stomach. Digestion. 1992;53(3-4):179–188. doi: 10.1159/000200993. [DOI] [PubMed] [Google Scholar]
  17. Ekman L., Hansson E., Havu N., Carlsson E., Lundberg C. Toxicological studies on omeprazole. Scand J Gastroenterol Suppl. 1985;108:53–69. [PubMed] [Google Scholar]
  18. Freedman S. B., Patel S., Smith A. J., Chapman K., Fletcher A., Kemp J. A., Marshall G. R., Hargreaves R. J., Scholey K., Mellin E. C. A second generation of non-peptide cholecystokinin receptor antagonists and their possible therapeutic potential. Ann N Y Acad Sci. 1994 Mar 23;713:312–318. doi: 10.1111/j.1749-6632.1994.tb44079.x. [DOI] [PubMed] [Google Scholar]
  19. Fried M., Erlacher U., Schwizer W., Löchner C., Koerfer J., Beglinger C., Jansen J. B., Lamers C. B., Harder F., Bischof-Delaloye A. Role of cholecystokinin in the regulation of gastric emptying and pancreatic enzyme secretion in humans. Studies with the cholecystokinin-receptor antagonist loxiglumide. Gastroenterology. 1991 Aug;101(2):503–511. doi: 10.1016/0016-5085(91)90031-f. [DOI] [PubMed] [Google Scholar]
  20. Grider J. R., Makhlouf G. M. Distinct receptors for cholecystokinin and gastrin on muscle cells of stomach and gallbladder. Am J Physiol. 1990 Aug;259(2 Pt 1):G184–G190. doi: 10.1152/ajpgi.1990.259.2.G184. [DOI] [PubMed] [Google Scholar]
  21. Gu Z. F., Rossowski W. J., Coy D. H., Pradhan T. K., Jensen R. T. Chimeric galanin analogs that function as antagonists in the CNS are full agonists in gastrointestinal smooth muscle. J Pharmacol Exp Ther. 1993 Aug;266(2):912–918. [PubMed] [Google Scholar]
  22. Harro J., Vasar E., Bradwejn J. CCK in animal and human research on anxiety. Trends Pharmacol Sci. 1993 Jun;14(6):244–249. doi: 10.1016/0165-6147(93)90020-k. [DOI] [PubMed] [Google Scholar]
  23. Havu N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion. 1986;35 (Suppl 1):42–55. doi: 10.1159/000199381. [DOI] [PubMed] [Google Scholar]
  24. Hetzel D. J., Dent J., Reed W. D., Narielvala F. M., Mackinnon M., McCarthy J. H., Mitchell B., Beveridge B. R., Laurence B. H., Gibson G. G. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology. 1988 Oct;95(4):903–912. doi: 10.1016/0016-5085(88)90162-x. [DOI] [PubMed] [Google Scholar]
  25. Howard J. M., Knight M., Jensen R. T., Gardner J. D. Discovery of a cholecystokinin analogue with partial agonist activity. Am J Physiol. 1984 Sep;247(3 Pt 1):G261–G264. doi: 10.1152/ajpgi.1984.247.3.G261. [DOI] [PubMed] [Google Scholar]
  26. Huang S. C., Yu D. H., Wank S. A., Mantey S., Gardner J. D., Jensen R. T. Importance of sulfation of gastrin or cholecystokinin (CCK) on affinity for gastrin and CCK receptors. Peptides. 1989 Jul-Aug;10(4):785–789. doi: 10.1016/0196-9781(89)90114-9. [DOI] [PubMed] [Google Scholar]
  27. Huang S. C., Zhang L., Chiang H. C., Wank S. A., Maton P. N., Gardner J. D., Jensen R. T. Benzodiazepine analogues L365,260 and L364,718 as gastrin and pancreatic CCK receptor antagonists. Am J Physiol. 1989 Jul;257(1 Pt 1):G169–G174. doi: 10.1152/ajpgi.1989.257.1.G169. [DOI] [PubMed] [Google Scholar]
  28. Hughes J., Boden P., Costall B., Domeney A., Kelly E., Horwell D. C., Hunter J. C., Pinnock R. D., Woodruff G. N. Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci U S A. 1990 Sep;87(17):6728–6732. doi: 10.1073/pnas.87.17.6728. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Höcker M., Hughes J., Fölsch U. R., Schmidt W. E. PD 135158, a CCKB/gastrin receptor antagonist, stimulates rat pancreatic enzyme secretion as a CCKA receptor agonist. Eur J Pharmacol. 1993 Sep 21;242(1):105–108. doi: 10.1016/0014-2999(93)90016-b. [DOI] [PubMed] [Google Scholar]
  30. Jansen J. B., Klinkenberg-Knol E. C., Meuwissen S. G., De Bruijne J. W., Festen H. P., Snel P., Lückers A. E., Biemond I., Lamers C. B. Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis. Gastroenterology. 1990 Sep;99(3):621–628. doi: 10.1016/0016-5085(90)90946-x. [DOI] [PubMed] [Google Scholar]
  31. Jensen R. T., Coy D. H. Progress in the development of potent bombesin receptor antagonists. Trends Pharmacol Sci. 1991 Jan;12(1):13–19. doi: 10.1016/0165-6147(91)90483-9. [DOI] [PubMed] [Google Scholar]
  32. Jensen R. T., Qian J. M., Lin J. T., Mantey S. A., Pisegna J. R., Wank S. A. Distinguishing multiple CCK receptor subtypes. Studies with guinea pig chief cells and transfected human CCK receptors. Ann N Y Acad Sci. 1994 Mar 23;713:88–106. doi: 10.1111/j.1749-6632.1994.tb44055.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Jensen R. T., Wank S. A., Rowley W. H., Sato S., Gardner J. D. Interaction of CCK with pancreatic acinar cells. Trends Pharmacol Sci. 1989 Oct;10(10):418–423. doi: 10.1016/0165-6147(89)90192-2. [DOI] [PubMed] [Google Scholar]
  34. Karlsson S., Ahrén B. CCK-8-stimulated insulin secretion in vivo is mediated by CCKA receptors. Eur J Pharmacol. 1992 Mar 17;213(1):145–146. doi: 10.1016/0014-2999(92)90245-y. [DOI] [PubMed] [Google Scholar]
  35. Knapp R. J., Vaughn L. K., Fang S. N., Bogert C. L., Yamamura M. S., Hruby V. J., Yamamura H. I. A new, highly selective CCK-B receptor radioligand ([3H][N-methyl-Nle28,31]CCK26-33): evidence for CCK-B receptor heterogeneity. J Pharmacol Exp Ther. 1990 Dec;255(3):1278–1286. [PubMed] [Google Scholar]
  36. Koop I., Eissele R., Richter S., Patberg H., Meyer F., Mössner J., Arnold R., Koop H. A new CCK-B/gastrin receptor antagonist acts as an agonist on the rat pancreas. Int J Pancreatol. 1994 Jun;15(3):215–222. doi: 10.1007/BF02924197. [DOI] [PubMed] [Google Scholar]
  37. Kopin A. S., Beinborn M., Lee Y. M., McBride E. W., Quinn S. M. The CCK-B/gastrin receptor. Identification of amino acids that determine nonpeptide antagonist affinity. Ann N Y Acad Sci. 1994 Mar 23;713:67–78. doi: 10.1111/j.1749-6632.1994.tb44053.x. [DOI] [PubMed] [Google Scholar]
  38. Kopin A. S., Lee Y. M., McBride E. W., Miller L. J., Lu M., Lin H. Y., Kolakowski L. F., Jr, Beinborn M. Expression cloning and characterization of the canine parietal cell gastrin receptor. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3605–3609. doi: 10.1073/pnas.89.8.3605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Kopin A. S., McBride E. W., Quinn S. M., Kolakowski L. F., Jr, Beinborn M. The role of the cholecystokinin-B/gastrin receptor transmembrane domains in determining affinity for subtype-selective ligands. J Biol Chem. 1995 Mar 10;270(10):5019–5023. doi: 10.1074/jbc.270.10.5019. [DOI] [PubMed] [Google Scholar]
  40. Kuwahara T., Kudoh T., Nagase H., Takamiya M., Nakano A., Ohtsuka T., Yoshizaki H., Arisawa M. Tetronothiodin, a novel CCKB receptor ligand, antagonizes cholecystokinin-induced Ca2+ mobilization in a pituitary cell line. Eur J Pharmacol. 1992 Oct 6;221(1):99–105. doi: 10.1016/0014-2999(92)90777-2. [DOI] [PubMed] [Google Scholar]
  41. Kuwahara T., Kudoh T., Nakano A., Yoshizaki H., Takamiya M., Nagase H., Arisawa M. Species specificity of pharmacological characteristics of CCK-B receptors. Neurosci Lett. 1993 Aug 6;158(1):1–4. doi: 10.1016/0304-3940(93)90597-e. [DOI] [PubMed] [Google Scholar]
  42. Lam Y. K., Bogen D., Chang R. S., Faust K. A., Hensens O. D., Zink D. L., Schwartz C. D., Zitano L., Garrity G. M., Gagliardi M. M. Novel and potent gastrin and brain cholecystokinin antagonists from Streptomyces olivaceus. Taxonomy, fermentation, isolation, chemical conversions, and physico-chemical and biochemical properties. J Antibiot (Tokyo) 1991 Jun;44(6):613–625. doi: 10.7164/antibiotics.44.613. [DOI] [PubMed] [Google Scholar]
  43. Lamberts R., Creutzfeldt W., Strüber H. G., Brunner G., Solcia E. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology. 1993 May;104(5):1356–1370. doi: 10.1016/0016-5085(93)90344-c. [DOI] [PubMed] [Google Scholar]
  44. Lanas A. I., Anderson J. W., Uemura N., Hirschowitz B. I. Effects of cholinergic, histaminergic, and peptidergic stimulation on pepsinogen secretion by isolated human peptic cells. Scand J Gastroenterol. 1994 Aug;29(8):678–683. doi: 10.3109/00365529409092493. [DOI] [PubMed] [Google Scholar]
  45. Lee Y. M., Beinborn M., McBride E. W., Lu M., Kolakowski L. F., Jr, Kopin A. S. The human brain cholecystokinin-B/gastrin receptor. Cloning and characterization. J Biol Chem. 1993 Apr 15;268(11):8164–8169. [PubMed] [Google Scholar]
  46. Lehy T., Cadiot G., Mignon M., Ruszniewski P., Bonfils S. Influence of multiple endocrine neoplasia type 1 on gastric endocrine cells in patients with the Zollinger-Ellison syndrome. Gut. 1992 Sep;33(9):1275–1279. doi: 10.1136/gut.33.9.1275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Lin C. W., Bianchi B. R., Miller T. R., Witte D. G., Wolfram C. A. Both CCK-A and CCK-B/gastrin receptors mediate pepsinogen release in guinea pig gastric glands. Am J Physiol. 1992 Jun;262(6 Pt 1):G1113–G1120. doi: 10.1152/ajpgi.1992.262.6.G1113. [DOI] [PubMed] [Google Scholar]
  48. Lin C. W., Holladay M. W., Witte D. G., Miller T. R., Wolfram C. A., Bianchi B. R., Bennett M. J., Nadzan A. M. A71378: a CCK agonist with high potency and selectivity for CCK-A receptors. Am J Physiol. 1990 Apr;258(4 Pt 1):G648–G651. doi: 10.1152/ajpgi.1990.258.4.G648. [DOI] [PubMed] [Google Scholar]
  49. Lloyd K. C., Raybould H. E., Walsh J. H. Cholecystokinin inhibits gastric acid secretion through type "A" cholecystokinin receptors and somatostatin in rats. Am J Physiol. 1992 Sep;263(3 Pt 1):G287–G292. doi: 10.1152/ajpgi.1992.263.3.G287. [DOI] [PubMed] [Google Scholar]
  50. Makovec F., Peris W., Revel L., Giovanetti R., Mennuni L., Rovati L. C. Structure-antigastrin activity relationships of new (R)-4-benzamido-5-oxopentanoic acid derivatives. J Med Chem. 1992 Jan;35(1):28–38. doi: 10.1021/jm00079a003. [DOI] [PubMed] [Google Scholar]
  51. Mantyh C. R., Pappas T. N., Vigna S. R. Localization of cholecystokinin A and cholecystokinin B/gastrin receptors in the canine upper gastrointestinal tract. Gastroenterology. 1994 Oct;107(4):1019–1030. doi: 10.1016/0016-5085(94)90226-7. [DOI] [PubMed] [Google Scholar]
  52. Menozzi D., Gardner J. D., Jensen R. T., Maton P. N. Properties of receptors for gastrin and CCK on gastric smooth muscle cells. Am J Physiol. 1989 Jul;257(1 Pt 1):G73–G79. doi: 10.1152/ajpgi.1989.257.1.G73. [DOI] [PubMed] [Google Scholar]
  53. Metz D. C., Strader D. B., Orbuch M., Koviack P. D., Feigenbaum K. M., Jensen R. T. Use of omeprazole in Zollinger-Ellison syndrome: a prospective nine-year study of efficacy and safety. Aliment Pharmacol Ther. 1993 Dec;7(6):597–610. doi: 10.1111/j.1365-2036.1993.tb00140.x. [DOI] [PubMed] [Google Scholar]
  54. Meyer B. M., Werth B. A., Beglinger C., Hildebrand P., Jansen J. B., Zach D., Rovati L. C., Stalder G. A. Role of cholecystokinin in regulation of gastrointestinal motor functions. Lancet. 1989 Jul 1;2(8653):12–15. doi: 10.1016/s0140-6736(89)90255-9. [DOI] [PubMed] [Google Scholar]
  55. Murphy M. G., Sytnik B., Kovacs T. O., Mertz H., Ewanik D., Shingo S., Lin J. H., Gertz B. J., Walsh J. H. The gastrin-receptor antagonist L-365,260 inhibits stimulated acid secretion in humans. Clin Pharmacol Ther. 1993 Nov;54(5):533–539. doi: 10.1038/clpt.1993.185. [DOI] [PubMed] [Google Scholar]
  56. Mutt V., Jorpes J. E. Structure of porcine cholecystokinin-pancreozymin. 1. Cleavage with thrombin and with trypsin. Eur J Biochem. 1968 Oct 17;6(1):156–162. doi: 10.1111/j.1432-1033.1968.tb00433.x. [DOI] [PubMed] [Google Scholar]
  57. Nishida A., Miyata K., Tsutsumi R., Yuki H., Akuzawa S., Kobayashi A., Kamato T., Ito H., Yamano M., Katuyama Y. Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther. 1994 May;269(2):725–731. [PubMed] [Google Scholar]
  58. Nishida A., Takinami Y., Yuki H., Kobayashi A., Akuzawa S., Kamato T., Ito H., Yamano M., Nagakura Y., Miyata K. YM022 [(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl- 1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea], a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats. J Pharmacol Exp Ther. 1994 Sep;270(3):1256–1261. [PubMed] [Google Scholar]
  59. Ohtsuka T., Kotaki H., Nakayama N., Itezono Y., Shimma N., Kudoh T., Kuwahara T., Arisawa M., Yokose K., Seto H. Tetronothiodin, a novel cholecystokinin type-B receptor antagonist produced by Streptomyces sp. NR0489. II. Isolation, characterization and biological activities. J Antibiot (Tokyo) 1993 Jan;46(1):11–17. doi: 10.7164/antibiotics.46.11. [DOI] [PubMed] [Google Scholar]
  60. Ohtsuka T., Nakayama N., Itezono Y., Shimma N., Kuwahara T., Yokose K., Seto H. Tetronothiodin, a novel cholecystokinin type-B receptor antagonist produced by Streptomyces sp. NR0489. III. Structural elucidation. J Antibiot (Tokyo) 1993 Jan;46(1):18–24. doi: 10.7164/antibiotics.46.18. [DOI] [PubMed] [Google Scholar]
  61. Orbuch M., Venzon D. J., Lubensky I. A., Weber H. C., Gibril F., Jensen R. T. Prolonged hypergastrinemia does not increase the frequency of colonic neoplasia in patients with Zollinger-Ellison syndrome. Dig Dis Sci. 1996 Mar;41(3):604–613. doi: 10.1007/BF02282349. [DOI] [PubMed] [Google Scholar]
  62. Patel S., Chapman K. L., Smith A. J., Heald A., Freedman S. B. Use of ex vivo binding to estimate brain penetration and central activity of CCK-B antagonists. Ann N Y Acad Sci. 1994 Mar 23;713:360–363. doi: 10.1111/j.1749-6632.1994.tb44093.x. [DOI] [PubMed] [Google Scholar]
  63. Patel S., Smith A. J., Chapman K. L., Fletcher A. E., Kemp J. A., Marshall G. R., Hargreaves R. J., Ryecroft W., Iversen L. L., Iversen S. D. Biological properties of the benzodiazepine amidine derivative L-740,093, a cholecystokinin-B/gastrin receptor antagonist with high affinity in vitro and high potency in vivo. Mol Pharmacol. 1994 Nov;46(5):943–948. [PubMed] [Google Scholar]
  64. Pendley C. E., Fitzpatrick L. R., Capolino A. J., Davis M. A., Esterline N. J., Jakubowska A., Bertrand P., Guyon C., Dubroeucq M. C., Martin G. E. RP 73870, a gastrin/cholecystokinin-B receptor antagonist with potent anti-ulcer activity in the rat. J Pharmacol Exp Ther. 1995 Jun;273(3):1015–1022. [PubMed] [Google Scholar]
  65. Pisegna J. R., de Weerth A., Huppi K., Wank S. A. Molecular cloning of the human brain and gastric cholecystokinin receptor: structure, functional expression and chromosomal localization. Biochem Biophys Res Commun. 1992 Nov 30;189(1):296–303. doi: 10.1016/0006-291x(92)91557-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Pradhan T. K., Qian J. M., Sutliff V. E., Mantey S. A., Jensen R. T. Identification of CCK-A receptors on chief cells with use of a novel, highly selective ligand. Am J Physiol. 1995 Apr;268(4 Pt 1):G605–G612. doi: 10.1152/ajpgi.1995.268.4.G605. [DOI] [PubMed] [Google Scholar]
  67. Prinz C., Scott D. R., Hurwitz D., Helander H. F., Sachs G. Gastrin effects on isolated rat enterochromaffin-like cells in primary culture. Am J Physiol. 1994 Oct;267(4 Pt 1):G663–G675. doi: 10.1152/ajpgi.1994.267.4.G663. [DOI] [PubMed] [Google Scholar]
  68. Qian J. M., Rowley W. H., Jensen R. T. Gastrin and CCK activate phospholipase C and stimulate pepsinogen release by interacting with two distinct receptors. Am J Physiol. 1993 Apr;264(4 Pt 1):G718–G727. doi: 10.1152/ajpgi.1993.264.4.G718. [DOI] [PubMed] [Google Scholar]
  69. Rasmussen K., Czachura J. F., Stockton M. E., Howbert J. J. Electrophysiological effects of diphenylpyrazolidinone cholecystokinin-B and cholecystokinin-A antagonists on midbrain dopamine neurons. J Pharmacol Exp Ther. 1993 Jan;264(1):480–488. [PubMed] [Google Scholar]
  70. Rehfeld J. F. Gastrin and colorectal cancer: a never-ending dispute? Gastroenterology. 1995 Apr;108(4):1307–1310. doi: 10.1016/0016-5085(95)90234-1. [DOI] [PubMed] [Google Scholar]
  71. Rehfeld J. F., van Solinge W. W. The tumor biology of gastrin and cholecystokinin. Adv Cancer Res. 1994;63:295–347. doi: 10.1016/s0065-230x(08)60403-0. [DOI] [PubMed] [Google Scholar]
  72. Schmassmann A., Garner A., Flogerzi B., Hasan M. Y., Sanner M., Varga L., Halter F. Cholecystokinin type B receptor antagonist PD-136,450 is a partial secretory agonist in the stomach and a full agonist in the pancreas of the rat. Gut. 1994 Feb;35(2):270–274. doi: 10.1136/gut.35.2.270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Showell G. A., Bourrain S., Neduvelil J. G., Fletcher S. R., Baker R., Watt A. P., Fletcher A. E., Freedman S. B., Kemp J. A., Marshall G. R. High-affinity and potent, water-soluble 5-amino-1,4-benzodiazepine CCKB/gastrin receptor antagonists containing a cationic solubilizing group. J Med Chem. 1994 Mar 18;37(6):719–721. doi: 10.1021/jm00032a002. [DOI] [PubMed] [Google Scholar]
  74. Soll A. H., Amirian D. A., Thomas L. P., Reedy T. J., Elashoff J. D. Gastrin receptors on isolated canine parietal cells. J Clin Invest. 1984 May;73(5):1434–1447. doi: 10.1172/JCI111348. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Sutliff V. E., Cherner J. A., Jensen R. T., Gardner J. D. Binding of 125I-CCK-8 and 125I-gastrin-I to dispersed chief cells from guinea-pig stomach. Biochim Biophys Acta. 1990 Apr 9;1052(1):9–16. doi: 10.1016/0167-4889(90)90050-n. [DOI] [PubMed] [Google Scholar]
  76. Tang L. H., Miller M. D., Goldenring J. R., Modlin I. M., Hersey S. J. Partial agonism by gastrin for a cholecystokinin receptor mediating pepsinogen secretion. Am J Physiol. 1993 Nov;265(5 Pt 1):G865–G872. doi: 10.1152/ajpgi.1993.265.5.G865. [DOI] [PubMed] [Google Scholar]
  77. Tazi-Saad K., Chariot J., Rozé C. Control of pepsin secretion by regulatory peptides in the rat stomach: comparison with acid secretion. Peptides. 1992 Mar-Apr;13(2):233–239. doi: 10.1016/0196-9781(92)90102-9. [DOI] [PubMed] [Google Scholar]
  78. Wang L. H., Coy D. H., Taylor J. E., Jiang N. Y., Moreau J. P., Huang S. C., Frucht H., Haffar B. M., Jensen R. T. des-Met carboxyl-terminally modified analogues of bombesin function as potent bombesin receptor antagonists, partial agonists, or agonists. J Biol Chem. 1990 Sep 15;265(26):15695–15703. [PubMed] [Google Scholar]
  79. Wank S. A. Cholecystokinin receptors. Am J Physiol. 1995 Nov;269(5 Pt 1):G628–G646. doi: 10.1152/ajpgi.1995.269.5.G628. [DOI] [PubMed] [Google Scholar]
  80. Wank S. A., Pisegna J. R., de Weerth A. Cholecystokinin receptor family. Molecular cloning, structure, and functional expression in rat, guinea pig, and human. Ann N Y Acad Sci. 1994 Mar 23;713:49–66. doi: 10.1111/j.1749-6632.1994.tb44052.x. [DOI] [PubMed] [Google Scholar]
  81. Wormsley K. G. Is chronic long-term inhibition of gastric secretion really dangerous? Scand J Gastroenterol Suppl. 1988;146:166–174. doi: 10.3109/00365528809099143. [DOI] [PubMed] [Google Scholar]
  82. Yu D. H., Huang S. C., Wank S. A., Mantey S., Gardner J. D., Jensen R. T. Pancreatic receptors for cholecystokinin: evidence for three receptor classes. Am J Physiol. 1990 Jan;258(1 Pt 1):G86–G95. doi: 10.1152/ajpgi.1990.258.1.G86. [DOI] [PubMed] [Google Scholar]
  83. van Megen H. J., Westenberg H. G., den Boer J. A., Haigh J. R., Traub M. Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients. Psychopharmacology (Berl) 1994 Apr;114(3):449–455. doi: 10.1007/BF02249335. [DOI] [PubMed] [Google Scholar]

Articles from The Yale Journal of Biology and Medicine are provided here courtesy of Yale Journal of Biology and Medicine

RESOURCES